Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MMSI
stocks logo

MMSI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
388.35M
+9.35%
0.952
+2.37%
378.57M
+6.53%
0.889
+3.36%
406.14M
+6.19%
1.049
+3.85%
Estimates Revision
The market is revising Upward the revenue expectations for Merit Medical Systems, Inc. (MMSI) for FY2025, with the revenue forecasts being adjusted by 0.61% over the past three months. During the same period, the stock price has changed by -9.55%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.61%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.42%
In Past 3 Month
Stock Price
Go Down
down Image
-9.55%
In Past 3 Month
Wall Street analysts forecast MMSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MMSI is 100.57 USD with a low forecast of 90.00 USD and a high forecast of 109.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast MMSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MMSI is 100.57 USD with a low forecast of 90.00 USD and a high forecast of 109.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 84.090
sliders
Low
90.00
Averages
100.57
High
109.00
Current: 84.090
sliders
Low
90.00
Averages
100.57
High
109.00
Canaccord
John Young
Buy
downgrade
$104 -> $93
2025-11-14
Reason
Canaccord
John Young
Price Target
$104 -> $93
2025-11-14
downgrade
Buy
Reason
Canaccord analyst John Young lowered the firm's price target on Merit Medical to $93 from $104 and keeps a Buy rating on the shares. The firm noted the company's announement that CMS had notified the company that its application for Transitional Pass-Through, which would have provided incremental reimbursement for Wrapsody in the outpatient and ASC settings, would require further consideration from CMS prior to it making a final decision.
Wells Fargo
Larry Biegelsen
Overweight
downgrade
$103 -> $95
2025-11-14
Reason
Wells Fargo
Larry Biegelsen
Price Target
$103 -> $95
2025-11-14
downgrade
Overweight
Reason
Wells Fargo analyst Larry Biegelsen lowered the firm's price target on Merit Medical to $95 from $103 and keeps an Overweight rating on the shares. The firm notes the company withdrew Wrapsody's TPT bid after CMS pushed approval to 2027, with management pivoting to full U.S. launch under a new strategy. Missteps have hurt potential Wrapsody upside and management credibility, but strong core business momentum supports Wells' bullish stance.
Barrington
Outperform
maintain
$103 -> $106
2025-10-31
Reason
Barrington
Price Target
$103 -> $106
2025-10-31
maintain
Outperform
Reason
Barrington raised the firm's price target on Merit Medical to $106 from $103 and keeps an Outperform rating on the shares after the company reported "strong" Q3 results and increased its FY25 guidance "materially."
Piper Sandler
Overweight
maintain
$105 -> $109
2025-10-31
Reason
Piper Sandler
Price Target
$105 -> $109
2025-10-31
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Merit Medical to $109 from $105 and keeps an Overweight rating on the shares. The firm notes the company announced Q3 results that once again beat at both the top and bottom lines with 8% organic revenue growth and 9c EPS beat, but it may have been the gross margin upside in Q3 that was most impressive in the period. Full year guidance was raised as well, but in typical Merit Medical fashion Piper sees the implied guide for Q4 as being set in a prudent/responsible way.
Baird
David Rescott
Outperform
maintain
$102 -> $103
2025-10-31
Reason
Baird
David Rescott
Price Target
$102 -> $103
2025-10-31
maintain
Outperform
Reason
Baird analyst David Rescott raised the firm's price target on Merit Medical to $103 from $102 and keeps an Outperform rating on the shares. The firm updated its model following impressive Q3 results but where volatility remains ahead of its TPT update.
Canaccord
John Young
Buy
maintain
$103 -> $104
2025-10-16
Reason
Canaccord
John Young
Price Target
$103 -> $104
2025-10-16
maintain
Buy
Reason
Canaccord analyst John Young raised the firm's price target on Merit Medical to $104 from $103 and keeps a Buy rating on the shares. The firm updated its model following the announcement of a proposed acquisition from PENTAX Medical pf its C2 CryoBalloon Ablation System; a focal ablation system that expands Merit's Endoscopy product portfolio and will complement its acquisition of Endogastric Solutions that it made last year.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Merit Medical Systems Inc (MMSI.O) is 21.60, compared to its 5-year average forward P/E of 25.90. For a more detailed relative valuation and DCF analysis to assess Merit Medical Systems Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
25.90
Current PE
21.60
Overvalued PE
29.32
Undervalued PE
22.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
17.75
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
19.52
Undervalued EV/EBITDA
15.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.37
Current PS
0.00
Overvalued PS
3.76
Undervalued PS
2.98
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 999.05% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 999.05% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MMSI News & Events

Events Timeline

(ET)
2025-12-01
08:41:00
Massimo Approves Bitcoin Inclusion in Long-Term Treasury Reserve Strategy
select
2025-11-13 (ET)
2025-11-13
17:14:01
CMS informs Merit that additional review is needed for Wrapsody reimbursement.
select
2025-11-05 (ET)
2025-11-05
09:15:11
Merit Medical unveils 24-month effectiveness findings from AVF segment of WAVE trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-22NASDAQ.COM
Merit Medical (MMSI) Receives Upgrade to Buy: Implications for the Stock

  • Merit Medical Upgrade: Merit Medical (MMSI) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price.

  • Zacks Rating System: The Zacks rating system, which evaluates stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988.

  • Earnings Estimates: Analysts have raised their earnings estimates for Merit Medical, with the Zacks Consensus Estimate increasing by 0.1% over the past three months, suggesting an improvement in the company's underlying business.

  • Investment Opportunity: The upgrade places Merit Medical in the top 20% of Zacks-covered stocks, indicating potential for market-beating returns, making it an attractive investment opportunity for investors.

[object Object]
Preview
8.0
11-21NASDAQ.COM
Options Trading for Merit Medical Systems (MMSI) in the First Week of July 2026

  • Put Contract Overview: The $85.00 put contract has a bid of $6.90, allowing investors to buy MMSI shares at an effective cost of $78.10, which is attractive compared to the current price of $85.81. There is a 59% chance the contract may expire worthless, offering an 8.12% return on cash commitment.

  • Call Contract Overview: The $90.00 call contract has a bid of $5.70, enabling investors to sell MMSI shares at that price, potentially yielding an 11.53% return if exercised. There is a 50% chance this contract may also expire worthless, providing a 6.64% additional return if it does.

  • Volatility Insights: The implied volatility for the put contract is 35%, while the call contract has an implied volatility of 31%. The actual trailing twelve-month volatility is calculated at 30%.

  • YieldBoost Concept: Both put and call contracts offer a "YieldBoost," with the put providing a 12.45% annualized return if it expires worthless, and the call offering a 10.19% annualized return under similar conditions.

[object Object]
Preview
4.0
11-15Benzinga
Barrington Research Reaffirms Outperform Rating for Merit Medical Systems with $106 Price Target

  • Real-time Intelligence: Benzinga Pro offers fast and accurate stock market intelligence to help traders make informed decisions.

  • Exclusive Stories: The platform provides exclusive news stories generated by Benzinga reporters, enhancing the trading experience for its users.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Merit Medical Systems Inc (MMSI) stock price today?

The current price of MMSI is 84.09 USD — it has decreased -0.24 % in the last trading day.

arrow icon

What is Merit Medical Systems Inc (MMSI)'s business?

Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.

arrow icon

What is the price predicton of MMSI Stock?

Wall Street analysts forecast MMSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MMSI is 100.57 USD with a low forecast of 90.00 USD and a high forecast of 109.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Merit Medical Systems Inc (MMSI)'s revenue for the last quarter?

Merit Medical Systems Inc revenue for the last quarter amounts to 384.16M USD, increased 13.04 % YoY.

arrow icon

What is Merit Medical Systems Inc (MMSI)'s earnings per share (EPS) for the last quarter?

Merit Medical Systems Inc. EPS for the last quarter amounts to 0.46 USD, decreased -4.17 % YoY.

arrow icon

What changes have occurred in the market's expectations for Merit Medical Systems Inc (MMSI)'s fundamentals?

The market is revising Upward the revenue expectations for Merit Medical Systems, Inc. (MMSI) for FY2025, with the revenue forecasts being adjusted by 0.61% over the past three months. During the same period, the stock price has changed by -9.55%.
arrow icon

How many employees does Merit Medical Systems Inc (MMSI). have?

Merit Medical Systems Inc (MMSI) has 7400 emplpoyees as of December 05 2025.

arrow icon

What is Merit Medical Systems Inc (MMSI) market cap?

Today MMSI has the market capitalization of 4.99B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free